23andMe Investor Day Presentation Deck

FY2022 Highlights Advanced a wholly owned immuno-oncology program into Phase 1 study • Acquired Lemonaid Health to expand into Primary Care and Pharmacy Received FDA clearance for HOXB13 hereditary prostate cancer Released 14 new genetic health predisposition reports Reported on key genetic research findings on COVID-19, reproductive lifespan in women, depression, Parkinson's disease, and more ● ● ● Added a new ancestry analysis, including additional insights into some customers' indigenous genetic ancestry from North America and ancestral connections to 25 African ethnolinguistic groups Copyright © 2022 23andMe, Inc. 23andMe 6

View entire presentation